Peripheral cytokine as a pan-cancer predictor for immunotherapy with anti-PD-1/PD-L1 antibody.

e15044Background: Currently, only a small proportion of cancer patients may benefit from anti-PD-1/PD-L1 immune checkpoint inhibition (ICI), suggesting an urgent need for effective biomarkers. Due ...